Evidence map›Paper›PMID 30998908›Full record

ReviewChest2019

Radiation-Induced Lung Injury: Assessment and Management.

Alexander N Hanania, Walker Mainwaring, Yohannes T Ghebre, Nicola A Hanania, Michelle Ludwig

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06079931 (The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Patients), which is not on this map. Cited by 371 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
371citing papers in PubMed, 2 pooled it
37.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06079931 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Clinical Trial

TypeinterventionalSponsorFifth Affiliated Hospital, Sun Yat-Sen UniversityRan2024 to 2025Enrolled30ConditionsRadiation PneumonitisArmsBabaodan Capsule
3 · Its place in the literature

Who cites it

371 citing papers in PubMed, 2 syntheses or guidelines pooled it, 574 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  19. Article
  20. Article

311 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexander N HananiaDepartment of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
Walker MainwaringDepartment of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
Yohannes T GhebreDepartment of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX.
Nicola A HananiaSection of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX. Electronic address: hanania@bcm.edu.
Michelle LudwigDepartment of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
Baylor College of Medicine · US

Funding

Combination of PPI and pirfenidone to enhance antifibrotic efficacyR01HL137703 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GHEBRE, YOHANNES T · 2017 to 2021
$2.0M
DDAH As a Novel Target in Pulmonary FibrosisK01HL118683 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GHEBRE, YOHANNES T · 2013 to 2017
$682k
Repurposing esomeprazole for the treatment of sclerodermaR56AR077445 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI GHEBRE, YOHANNES T · 2020 to 2020
$352k
NHLBI NIH HHS K01 HL118683NHLBI NIH HHS R01 HL137703NIAMS NIH HHS R56 AR077445
6 · The paper itself

Abstract

Radiation-induced lung injury (RILI) encompasses any lung toxicity induced by radiation therapy (RT) and manifests acutely as radiation pneumonitis and chronically as radiation pulmonary fibrosis. Because most patients with thoracic and breast malignancies are expected to undergo RT in their lifetime, many with curative intent, the population at risk is significant. Furthermore, indications for thoracic RT are expanding given the advent of stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) for early-stage lung cancer in nonsurgical candidates as well as oligometastatic pulmonary disease from any solid tumor. Fortunately, the incidence of serious pulmonary complications from RT has decreased secondary to advances in radiation delivery techniques. Understanding the temporal relationship between RT and injury as well as the patient, disease, and radiation factors that help distinguish RILI from other etiologies is necessary to prevent misdiagnosis. Although treatment of acute pneumonitis is dependent on clinical severity and typically responds completely to corticosteroids, accurately diagnosing and identifying patients who may progress to fibrosis is challenging. Current research advances include high-precision radiation techniques, an improved understanding of the molecular basis of RILI, the development of small and large animal models, and the identification of candidate drugs for prevention and treatment.

Indexed as

HumansLung InjuryNeoplasmsPulmonary FibrosisRadiation InjuriesRadiation Pneumonitiscancerfibrosislung injurypneumonitisradiationthoracic

Identifiers

PMID30998908
PMCPMC8097634
OpenAlexW2938870751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.